Dmitry Zamansky Sells 6,243 Shares of American Well (NYSE:AMWL) Stock

American Well Corporation (NYSE:AMWL) insider Dmitry Zamansky sold 6,243 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $4.85, for a total transaction of $30,278.55. Following the sale, the insider directly owned 191,468 shares in the company, valued at $928,619.80. This trade represents a 3.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

American Well Price Performance

Shares of NYSE:AMWL opened at $5.37 on Wednesday. The firm has a fifty day moving average price of $4.42 and a two-hundred day moving average price of $6.13. The company has a market cap of $87.86 million, a price-to-earnings ratio of -0.75 and a beta of 1.26. American Well Corporation has a one year low of $3.71 and a one year high of $12.95.

American Well (NYSE:AMWL) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($1.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.83) by $0.09. American Well had a negative return on equity of 39.80% and a negative net margin of 42.80%.The company had revenue of $56.29 million for the quarter, compared to the consensus estimate of $54.56 million. Equities research analysts expect that American Well Corporation will post -9.34 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AMWL has been the subject of several research analyst reports. Wall Street Zen lowered shares of American Well from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of American Well in a report on Wednesday, October 8th. Wells Fargo & Company cut their target price on shares of American Well from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Stifel Nicolaus lowered their price target on American Well from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Wednesday, November 5th. Finally, Morgan Stanley dropped their price target on American Well from $10.50 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, December 18th. One research analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $7.58.

Hedge Funds Weigh In On American Well

A number of large investors have recently added to or reduced their stakes in AMWL. Headlands Technologies LLC purchased a new stake in American Well during the second quarter valued at about $39,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of American Well in the 3rd quarter valued at about $62,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of American Well in the 2nd quarter valued at about $89,000. Engineers Gate Manager LP purchased a new stake in American Well during the 2nd quarter valued at about $101,000. Finally, Prelude Capital Management LLC bought a new position in American Well during the 3rd quarter worth approximately $86,000. Hedge funds and other institutional investors own 56.05% of the company’s stock.

American Well Company Profile

American Well, operating under the trade name Amwell, is a Boston-based digital health company that develops and delivers telehealth solutions to healthcare providers, payers, employers and patients. Through its cloud-based platform, the company enables secure virtual visits, remote patient monitoring and integrated care coordination across a range of medical disciplines, including primary care, behavioral health, chronic disease management and urgent care.

The company’s core offering, the Amwell Telehealth Platform, facilitates live video consultations, asynchronous messaging, e-prescribing and electronic health record integration.